China SXT Pharmaceuticals (NASDAQ:SXTC) Shares to Reverse Split on Monday, August 10th

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC)’s stock is scheduled to reverse split before the market opens on Monday, August 10th. The 1-80 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 9th.

China SXT Pharmaceuticals Trading Down 19.6%

China SXT Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, reaching $0.05. The stock had a trading volume of 46,705,100 shares, compared to its average volume of 112,669,208. China SXT Pharmaceuticals has a twelve month low of $0.05 and a twelve month high of $1,046.98. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The firm’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $2.66.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.26 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in shares of China SXT Pharmaceuticals during the 4th quarter valued at $36,000. Virtu Financial LLC grew its holdings in shares of China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals in the third quarter worth $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.